Global pharmaceutical industry competition and shifts

The global pharmaceutical industry is experiencing significant structural shifts as China transitions from a generic manufacturer to a major leader in biopharmaceutical research and development. Reports indicate that China’s share of original compounds has risen significantly, with the country now accounting for nearly one-third of the global biopharma pipeline. This puts China in close competition with the United States, which holds a 35% share, while Europe’s market share has declined.

China’s growth is characterized by leadership in experimental therapies, including oncology, bispecific antibodies, and antibody-drug conjugates. This expansion is supported by massive capital injections, talent repatriation, and regulatory deregulation.

In response to this rising competition and the demand for personalized medicine, Western companies—particularly in Europe—are facing challenges such as rising costs, inflation, and fragile supply chains. Industry analysts suggest that to remain competitive, firms must invest in digital technologies like artificial intelligence and robotics to increase manufacturing efficiency.